Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYPS sarilumab pediatric sJIA dose-finding study
2024-512701-11-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 2, open-label trial of sarilumab in systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum serum concentration observed, Area under the serum concentration-time curve during a dose interval and 1 more. Planned start Aug 2018; status: authorised.
02
Drugs
sarilumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2024-512701-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512701-11-00.